drugset / Trial / NCT05951855
Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor combined with chidamide in the treatment of unfit R/R AML.
Timeline
- Start
- 2023-03-01
- Primary completion
- 2024-09-01
- Completion
- 2025-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | 40 mg | Oral |
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |
| Subject | Tucidinostat | Small molecule | 10 mg | Oral |